-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
-
-
-
-
-
-
-
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
-
-
-
-
-
-
-
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
-
-
-
-
-
-
-
AbbVie (ABBV), Neurocrine Biosciences (NBIX) Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
-
-
-
-
-
-
-
Neurocrine Biosciences Reports Third Quarter 2017 Results
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): KOL Call Implies Ingrezza Approval in '17 - Needham
-
-
-
-
-
-
-
Needham & Company Remains Bullish on Neurocrine Biosciences (NBIX) Following FDA Announcement
-
15,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

